Concepedia

Publication | Open Access

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

DOIFull Paper Access

17

Citations

26

References

2022

Year

Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick J. Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam,
EClinicalMedicine

References

YearCitations

Page 1